Age-Related Macular Degeneration (AMD) Treatment Technology Market Trends Expected to Emerge and Grow During 2017 - 2025

Albany, NY -- (SBWIRE) -- 01/23/2018 -- Age-related macular degeneration (AMD) is a health issue associated with the retina. According to the National Medical Research Council (Singapore), age-related macular degeneration accounts for 8%-7% of the total blindness cases worldwide. It is the most common cause of blindness in developed countries, particularly in people aged above 60 years. AMD occurs when a piece of the retina called the macula is harmed. The patient suffering from AMD can lose the focal vision. A patient cannot see fine points of interest, regardless of whether he/she is taking a gander at something close or far. In any case, the fringe (side) vision is normal. In a few patients, AMD progresses so gradually that vision loss does not occur for quite a while. In others, the sickness advances more rapidly and is likely to result in loss of vision in one or both eyes. Depending on the cause of macular degeneration, the treatment is started. The macular edema may take several months to recover. During this time, it is important to follow the treatment regimen more effectively. There exist three stage of AMD viz. early AMD, intermediate AMD, and late AMD.